Skip to main content
SpringerLink
Log in

Regulatory Normative of Nanomaterials for Their Use in Biomedicine

  • Chapter
  • First Online:
Nanoengineering Materials for Biomedical Uses

  • 356 Accesses

Abstract

With nanomedicines increasing in market value and disruptive potential, a rapidly moving field such as this will require engaging in the difficult task of responsible management and the development of appropriate guidelines, which falls into the jurisdiction of governmental agencies. While each is influenced by the countries politics and demands of the people, there are shared goals of improving market success, risk assessment, and safety optimization. In this chapter, we describe the regulatory landscape with regards to nanomedicines in various countries. We first start with the world’s nanotechnological leaders in North America, the European Union, and Asian and then discuss the notable strides taken by emerging countries where nanomedicines have caught the public eye.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Larsson S, Jansson M, Boholm Å. Expert stakeholders’ perception of nanotechnology: risk, benefit, knowledge, and regulation. J Nanopart Res. 2019;21(3):57.

    Article  Google Scholar 

  2. Corley EA, Scheufele DA, Hu Q. Of risks and regulations: how leading U.S. nanoscientists form policy stances about nanotechnology. J Nanopart Res. 2009;11(7):1573–85.

    Article  Google Scholar 

  3. Bowman DM, Hodge GA. Nanotechnology: mapping the wild regulatory frontier. Futures. 2006;38(9):1060–73.

    Article  Google Scholar 

  4. FDA’s approach to regulation of nanotechnology products. https://www.fda.gov/science-research/nanotechnology-programs-fda/fdas-approach-regulation-nanotechnology-products (2018). Accessed 23 May 2019.

  5. Nanotechnology task force. https://www.fda.gov/science-research/nanotechnology-programs-fda/nanotechnology-task-force (2019). Accessed 23 May 2019.

  6. Nanotechnology task force report 2007. https://www.fda.gov/science-research/nanotechnology-programs-fda/nanotechnology-task-force-report-2007 (2019). Accessed 24 May 2019.

  7. 2013 Nanotechnology regulatory science research plan. https://www.fda.gov/science-research/nanotechnology-programs-fda/2013-nanotechnology-regulatory-science-research-plan (2013). Accessed 23 May 2019.

  8. Research on nanomaterials. https://www.epa.gov/chemical-research/research-nanomaterials (2019). Accessed 24 May 2019.

  9. Control of nanoscale materials under the toxic substances control act. https://www.epa.gov/reviewing-new-chemicals-under-toxic-substances-control-act-tsca/control-nanoscale-materials-under (2019). Accessed 24 May 2019.

  10. Policy statement on health Canada’s working definition for nanomaterial. https://www.canada.ca/en/health-canada/services/science-research/reports-publications/nanomaterial/policy-statement-health-canada-working-definition.html (2019). Accessed 23 May 2019.

  11. Nanomaterials and their applications in textiles—standards. https://www.ic.gc.ca/eic/site/textiles-textiles.nsf/eng/h_tx03226.html (2019). Accessed 23 May 2019.

  12. Amenta V, Aschberger K, Arena M, Bouwmeester H, Botelho Moniz F, Brandhoff P, Gottardo S, Marvin HJP, Mech A, Quiros Pesudo L, et al. Regulatory aspects of nanotechnology in the agri/feed/food sector in EU and non-EU countries. Regul Toxicol Pharm. 2015;73(1):463–76.

    Article  Google Scholar 

  13. Joint action plan for the Canada-United States regulatory cooperation council. https://www.canada.ca/en/treasury-board-secretariat/corporate/transparency/acts-regulations/canada-us-regulatory-cooperation-council/joint-action-plan.html#s4.5.2 (2019). Accessed 23 May 2019.

  14. Vencken SF, Greene CM. A review of the regulatory framework for nanomedicines in the European Union. In: Grumezescu AM, editor. Elsevier Inc.; 2018. p. 641–79.

    Google Scholar 

  15. Pita R, Ehmann F, Papaluca M. Nanomedicines in the EU—regulatory overview. AAPS J. 2016;18(6):1576–82.

    Article  CAS  Google Scholar 

  16. D’Silva J, Van Calster G. Taking temperature—a review of European union regulation in nanomedicine. Eur J Health Law. 2009;16(3):249–69.

    Article  Google Scholar 

  17. Ehmann F, Sakai-Kato K, Duncan R, Pérez de la Ossa DH, Pita R, Vidal J-M, Kohli A, Tothfalusi L, Sanh A, Tinto S, et al. Next-generation nanomedicines and nanosimilars: EU regulators’ initiatives relating to the development and evaluation of nanomedicines. Nanomedicine 2013;8(5):849–56.

    Article  CAS  Google Scholar 

  18. Soares S, Sousa J, Pais A, Vitorino C. Nanomedicine: principles, properties, and regulatory issues. Front Chem. 2018;6:1–15.

    Article  Google Scholar 

  19. Satterstrom FK, Arcuri ASA, Davis TA, Gulledge W, Foss Hansen S, Shafy Haraza MA, Kapustka L, Karkan D, Linkov I, Melkonyan M, et al. Considerations for implementation of manufactured nanomaterial policy and governance. In: Linkov I, Steevens J, editors. Dordrecht: Springer; 2009. p. 329–51.

    Google Scholar 

  20. Trisolino A. Nanomedicine: building a bridge between science and law. NanoEthics. 2014;8(2):141–63.

    Article  Google Scholar 

  21. Teunenbroek TV, Baker J, Dijkzeul A. Towards a more effective and efficient governance and regulation of nanomaterials. Part Fibre Toxicol. 2017;14(54):1–5.

    Google Scholar 

  22. Canu IG, Schulte PA, Riediker M, Fatkhutdinova L, Bergamaschi E. Methodological, political and legal issues in the assessment of the effects of nanotechnology on human health. J Epidemiol Commun Health. 2018;72(2):148–53.

    Article  Google Scholar 

  23. Kreyling WG, Semmler-Behnke M, Chaudhry Q. A complementary definition of nanomaterial. Nano Today. 2010;5(3):165–8.

    Article  Google Scholar 

  24. Taniguchi N. On the basic concept of nano-technology. In: Proceedings of international conference on production engineering. London; 1974.

    Google Scholar 

  25. Iijima S. Helical microtubules of graphitic carbon. Nature. 1991;354(6348):56–8.

    Article  CAS  Google Scholar 

  26. StatNano. Japan indicators. https://statnano.com/country/japan (2019). Accessed 25 May 2019.

  27. Director General of Labour Standards Bureau M. Notification on precautionary measures for prevention of exposure etc. to and other effects of nanomaterials. In: Ministry of Health Law, editor. 2009.

    Google Scholar 

  28. Strategy CfRaD. Nanotechnology and materials R&D in Japan (2018): an overview and analysis. In: Unit NM, editor. 2018. p. 86.

    Google Scholar 

  29. Tolochko N. History of nanotechnology. In: Valeri NCB, Sae-Chul K, editors. Nanoscience and nanotechnologies. Encyclopedia of Life Support Systems (EOLSS). Oxford: Eolss Publishers; 2009.

    Google Scholar 

  30. Ministry of Education C, Sports, Science and Technology. Science and technology basic plan. http://www.mext.go.jp/en/policy/science_technology/lawandplan/title01/detail01/1375311.htm (2019). Accessed 28 May 2019.

  31. Office C. The 5th science and technology basic plan. In: Office C, editor. 2016.

    Google Scholar 

  32. Žagar A. Nanotech cluster and industry landscape in Japan. 2014.

    Google Scholar 

  33. Japan So. 2015 Population census. In e-Stat https://www.e-stat.go.jp/en/stat-search/files?page=1&toukei=00200521&tstat=000001080615&second=1 (2019). Accessed 28 May 2019.

  34. Worldometers. Japan population. https://www.worldometers.info/world-population/japan-population/ (2019). Accessed 29 May 2019.

  35. Bank TW. Japan. In data https://data.worldbank.org/country/japan (2019). Accessed 29 May 2019.

  36. Matteucci F, Giannantonio R, Calabi F, Agostiano A, Gigli G, Rossi M. Deployment and exploitation of nanotechnology nanomaterials and nanomedicine. In: AIP conference proceedings 2018; 1990.

    Google Scholar 

  37. Dube A, Ebrahim N. The nanomedicine landscape of South Africa. Nanotechnol Rev. 2017;6(4):339–44.

    Article  Google Scholar 

  38. Arcuri ASA, Grossi MGL, Pinto VRS, Rinaldi A, Pinto AC. Developing strategies in Brazil to manage the emerging nanotechnology and its associated risks. In: Linkov I, Steevens J, editors. Dordrecht: Springer; 2009. p. 299–309.

    Google Scholar 

  39. Jarvis SL, Richmond N. Regulation and governance of nanotechnology in China: regulatory challenges and effectiveness. Eur J Law Technol. 2011;2(3).

    Google Scholar 

  40. Bhatia P, Chugh A. A multilevel governance framework for regulation of nanomedicine in India. Nanotechnol Rev. 2017;6(4):373–82.

    Article  Google Scholar 

  41. Bhatia P, Vasaikar S, Wali A. A landscape of nanomedicine innovations in India. Nanotechnol Rev. 2018;7(2):131–48.

    Article  CAS  Google Scholar 

  42. Mishra M, Dashora K, Srivastava A, Fasake VD, Nag RH. Prospects, challenges and need for regulation of nanotechnology with special reference to India. Ecotoxicol Environ Saf. 2019;171:677–82.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Dr. Alarcon thanks the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC), Ministry of Economic Development, Job Creation and Trade for an Early Researcher Award, and the New Frontiers in Research Fund—Exploration for a research Grant. Ms. Lazurko thanks the Queen Elizabeth II Graduate Scholarships in Science and Technology for financial support. Dr. Ahumada thanks the CONICYT—FONDECYT (Iniciación en la Investigación) grant #11180616, and to FDP-Universidad Mayor grant #I-2019077.

Disclosures

All authors have read and approved the final version.

Author information

Authors and Affiliations

  1. Division of Cardiac Surgery, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada

    Caitlin Lazurko, Emilio I. Alarcon & Erik Jacques

  2. Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, K1H 8M5, Canada

    Caitlin Lazurko & Emilio I. Alarcon

  3. Facultad de Ciencias, Centro de Nanotecnología Aplicada, Universidad Mayor, Huechuraba, RM, Chile

    Manuel Ahumada

Authors
  1. Caitlin Lazurko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manuel Ahumada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emilio I. Alarcon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Erik Jacques
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erik Jacques .

Editor information

Editors and Affiliations

  1. Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, ON, Canada

    Emilio I. Alarcon

  2. Center for Applied Nanotechnology, Universidad Mayor, Santiago, RM, Chile

    Manuel Ahumada

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lazurko, C., Ahumada, M., Alarcon, E.I., Jacques, E. (2019). Regulatory Normative of Nanomaterials for Their Use in Biomedicine. In: Alarcon, E., Ahumada, M. (eds) Nanoengineering Materials for Biomedical Uses. Springer, Cham. https://doi.org/10.1007/978-3-030-31261-9_10

Download citation

Publish with us

Policies and ethics

Search

Navigation